Form 8-K - Current report:
SEC Accession No. 0001829126-25-002334
Filing Date
2025-04-02
Accepted
2025-04-02 16:42:24
Documents
18
Period of Report
2025-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cyclacel_8k.htm   iXBRL 8-K 45273
2 EXHIBIT 99.1 cyclacel_ex99-1.htm EX-99.1 58419
3 GRAPHIC img_001.jpg GRAPHIC 6677
4 GRAPHIC ex99-1_001.jpg GRAPHIC 5978
5 GRAPHIC ex99-1_002.jpg GRAPHIC 3980
  Complete submission text file 0001829126-25-002334.txt   368103

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cycc-20250331.xsd EX-101.SCH 3743
7 XBRL DEFINITION FILE cycc-20250331_def.xml EX-101.DEF 26581
8 XBRL LABEL FILE cycc-20250331_lab.xml EX-101.LAB 36613
9 XBRL PRESENTATION FILE cycc-20250331_pre.xml EX-101.PRE 25205
20 EXTRACTED XBRL INSTANCE DOCUMENT cyclacel_8k_htm.xml XML 5770
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50626 | Film No.: 25805480
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)